Mestag
London, GB · 4 known investors
Find your way into Mestag
858 people in our graph share verified history with the Mestag team — schools, employers, funds. One of them is your warm intro.
Anthony Philippakisunlockedknows Susan Hill · together at University of Cambridge (overlapped)
knows the team · via Mestag Therapeutics
×3knows the team · via Cornell
×3knows the team · via University of California, Berkeley
knows the team · via Merck Healthcare
×2knows the team · via University of Cambridge
Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures. The company advances agonist antibody programs and operates a RAFT target discovery platform to identify new therapeutic targets.
Founders & leadership
MB
Michael B. BrennerFounder
CB
Chris BuckleyFounder
MC
Mark ColesinFounderMark Coles led research at the Kennedy Institute of Rheumatology's Stromal and Systems Immunology Group, where he studied immune-stromal cell interactions in inflammatory diseases and cancer using experimental and computational methods, and oversaw the Digital Pathology Omics Core providing multiplex imaging services.
SR
Soumya RaychaudhuriFounder
DA
David A. TuvesonFounder
SH
Susan HillinChief Executive OfficerSusan Hill is CEO of Mestag Therapeutics, an immunology company developing antibody and platform-based treatments for cancer and inflammatory diseases. She has 25+ years of experience in biotech, pharma, and venture investing, including roles in business development, consulting, and operating positions across multiple companies, and currently serves as a venture partner at SV Health Investors.
Investors · 4
Founder mafia
2 people who came through Mestag went on to found or lead other companies.
Companies House · registry record
View on Companies House ↗- Registered name
- MESTAG LIMITED
- Company number
- SC366550
- Status
- Dissolved
- Company type
- Private limited company
- Incorporated
- 8 Oct 2009
- Dissolved
- 9 Mar 2012
- Registered office
- Coillemore, Newmore, Invergordon, Ross-Shire, IV18 0PG
- Nature of business (SIC)
- 25110 — Manufacture of metal structures and parts of structures
- Accounts
- last made up to 31 Oct 2010
Current officers
- Edmund Donald William Maclellan — secretary, appointed 8 Oct 2009
- James Kenneth Chalmers — director, appointed 8 Oct 2009
- Edmund Donald William Maclellan — director, appointed 8 Oct 2009
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Mestag do?
- Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures. The company advances agonist antibody programs and operates a RAFT target discovery platform to identify new therapeutic targets.
- Who founded Mestag?
- Mestag was founded by Michael B. Brenner, Chris Buckley, Mark Coles, Soumya Raychaudhuri, David A. Tuveson.
- Who are Mestag's investors?
- Mestag's investors include SV Health Investors, Forbion, GV (Google Ventures), Northpond Ventures.
- Where is Mestag headquartered?
- Mestag is headquartered in London, GB.